Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Livzon Pharmaceutical Group ( (HK:1513) ) is now available.
Livzon Pharmaceutical Group has announced the adoption of new terms of reference for its Audit Committee, which is composed of non-executive directors, with a majority being independent. This move is expected to enhance the company’s governance structure, aligning with the Hong Kong and Shenzhen Stock Exchange listing rules, and potentially boosting investor confidence.
The most recent analyst rating on (HK:1513) stock is a Buy with a HK$48.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products. The company is known for its commitment to innovation and quality in the healthcare sector.
Average Trading Volume: 1,513,250
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.39B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.